Fig. 2.

Lysis by in vitro peptide-primed specific T cells is Eps8-specific, HLA-A2.1-restricted. a Peptide-primed specific T cells were assessed for their cytotoxic activity against T2 cells pre-pulsed with Eps8-derived peptide (HLA-A2.1⁺, Eps8⁺), and T2 cells pre-pulsed with irrelevant peptide (HLA-A2.1⁺, Eps8⁻). b Cytotoxicity of peptide-primed specific T cells on MCF-7 breast cancer cells (HLA-A2.1⁺, Eps8⁺), MCF-7 plus Eps8-shRNA knockdown (HLA-A2.1⁺, Eps8⁻), and MCF-7 plus anti-HLA-A2 antibody (HLA-A2.1⁻, Eps8⁺) at a 50:1 E/T ratio. Experiments were performed in triplicate. Data are represented as the mean ± S.D. ^# P < 0.05, compared to the native counterpart; ^* P < 0.05, compared to vehicle control